Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome

Micro-Abstract We externally validated the MD Anderson proposed lower risk MDS model among 1288 patients. The median overall survival for the corresponding LR-MDAS categories was 109, 56 and 29 months respectively for each category. The model upstaged 25% of patients.

Saved in:
Bibliographic Details
Published inClinical lymphoma, myeloma and leukemia Vol. 15; pp. S60 - S63
Main Authors Komrokji, Rami, Ramadan, Hanadi, Al Ali, Najla, Corrales-Yepez, Maria, Zhang, Ling, Padron, Eric, Lancet, Jeffrey, List, Alan
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.06.2015
Subjects
Aged
Female
Hematology, Oncology and Palliative Medicine
Humans
IPSS
LR-MDAS
Male
MDS
Myelodysplastic Syndromes - mortality
Prognosis
Risk Assessment - methods
Risk Factors
Risk models
Survival Analysis
Prognosis
Risk models
IPSS
LR-MDAS
MDS
Online AccessGet full text

Cover

More Information
Summary:Micro-Abstract We externally validated the MD Anderson proposed lower risk MDS model among 1288 patients. The median overall survival for the corresponding LR-MDAS categories was 109, 56 and 29 months respectively for each category. The model upstaged 25% of patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2152-2650
2152-2669
DOI:10.1016/j.clml.2015.03.011